PureTech Health (LON:PRTC) Hits New 1-Year Low – Here’s What Happened

PureTech Health plc (LON:PRTC)’s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 134.80 ($1.66) and last traded at GBX 136.40 ($1.68), with a volume of 325557 shares trading hands. The stock had previously closed at GBX 138 ($1.70).

Analyst Ratings Changes

Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 455 ($5.60) target price on shares of PureTech Health in a research report on Monday, December 16th.

PureTech Health Price Performance

The stock has a market cap of £326.57 million, a P/E ratio of -593.04 and a beta of 1.02. The business has a 50 day simple moving average of GBX 157.66 and a 200-day simple moving average of GBX 159.51. The company has a debt-to-equity ratio of 47.27, a quick ratio of 2.51 and a current ratio of 3.68.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.